Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart versus IVIg in adults with CIDP
2024-520097-36-00Phase 3Authorised
- Sponsor
- argenx
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial of empasiprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by argenx. Primary endpoint: Decrease of at least 1 point from baseline in adjusted INCAT score at week 24. Planned start Jan 2026; status: authorised.
02
Drugs
empasiprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2024-520097-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520097-36-00.